SOT106, an investigational antibody-drug conjugate (ADC) developed by SOTIO Biotech, has now secured both orphan drug and fast track designations from the FDA for osteosarcoma and soft tissue sarcoma (STS) — making it the first agent to hold both designations across both indications. The drug hasn't entered clinical trials yet, but preclinical data have been encouraging enough to earn these regulatory milestones.

SOT106 works by targeting LRRC15, a protein broadly expressed across sarcoma subtypes but with limited presence in normal adult tissue — making it an attractive ADC target. Once bound, the drug is internalized and releases its payload (MMAE) inside the tumor cell to disrupt microtubule formation and trigger cell death. It also produces a "bystander effect," killing neighboring tumor cells. In preclinical models, it demonstrated tumor regression even in cases where earlier LRRC15-targeting agents failed.

Key Takeaways:

• SOT106 holds both orphan drug and fast track designations for osteosarcoma and STS — a dual designation across both indications
• Preclinical models showed complete responses across STS subtypes and activity in pediatric osteosarcoma models resistant to earlier LRRC15-targeting ADCs
• No clinical efficacy or safety data have been reported yet; a first-in-human trial is expected later in 2026

Why it matters: Sarcoma patients have long faced limited treatment options, and targeted therapies in this space remain scarce. SOT106's dual regulatory designations signal growing momentum for LRRC15-directed therapy and could represent a meaningful advance for patients with these rare, hard-to-treat cancers.